Right now, when you look at cost recovery, we are much lower than the U.S. The U.S. is probably $300,000 per submission. We go around $100,000 per submission. Again, it depends on the type of submission, but the average new active substance is $100,000, versus the U.S, which is $300,000, so we are much lower. We really need to look at our cost-recovery system once we've eliminated backlog.
On April 1st, 2008. See this statement in context.